We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Yield10 Bioscience Inc | NASDAQ:YTEN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0008 | 0.37% | 0.2168 | 0.216 | 0.2169 | 11,186 | 12:41:13 |
|
Megan N. Gates, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
(617) 542-6000
|
Large accelerated filer
o
|
|
Accelerated filer
o
|
Non-accelerated filer
o
|
|
Smaller reporting company
x
|
|
|
|
|
|
|
|
|
|
|||
Title of Securities
To Be Registered |
|
Amount
To Be Registered(1)(2) |
|
Proposed
Maximum Offering Price Per Share(3) |
|
Proposed
Maximum Aggregate Offering Price |
|
Amount of
Registration Fee(4) |
|||
2018 Stock Option and Incentive Plan
Common Stock, par value $0.01 per share
|
|
1,300,000
|
|
$
|
1.3095
|
|
$
|
1,702,350.00
|
|
$
|
211.94
|
(1)
|
This registration statement relates to 1,300,000 shares of common stock, $0.01 par value per share, of the Registrant (the “
Common Stock
”) reserved for issuance under the 2018 Stock Option and Incentive Plan (the “
2018 Plan
”).
|
|
|
(2)
|
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “
Securities Act
”), this registration statement shall also cover any additional shares of Common Stock which become issuable under the 2018 Plan by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of outstanding shares of Common Stock.
|
|
|
(3)
|
The price of $1.3095 per share, which is the average of the high and low sales price for a share of Common Stock as reported on the Nasdaq Capital Market on August 3, 2018, is set forth solely for purposes of calculating the registration fee pursuant to Rule 457(c) and (h) of the Securities Act.
|
|
|
(4)
|
Calculated pursuant to Section 6(b) of the Securities Act.
|
(a)
|
The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2017, filed on March 12, 2018 (File No. 001-33133);
|
(b)
|
The Registrant’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2018, filed on May 10, 2018, and for the quarter ended June 30, 2018, filed on August 9, 2018 (File No. 001-33133);
|
(c)
|
The Registrant’s Current Reports on Form 8-K filed on May 22, 2018 and May 24, 2018 (File No. 001-33133);
|
(d)
|
the portions of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 16, 2018 that are deemed “filed” with the Commission under the Securities Exchange Act of 1934, as amended (the “
Exchange Act
”) (File No. 001-33133); and
|
(e)
|
The section entitled “Description of Registrant’s Securities to be Registered” contained in the Registrant’s Registration Statement on Form 8-A, filed pursuant to Section 12(b) of the Exchange Act on November 6, 2006 (File No. 001-33133), including any amendment or report filed for the purpose of updating such description.
|
Exhibit No.
|
|
Description of Exhibit
|
|
Specimen Stock Certificate (filed as Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (No. 333-135760) on September 21, 2006 and incorporated herein by reference)
|
|
|
|
|
|
Opinion of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C.
|
|
|
|
|
|
Consent of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. (included in Exhibit 5.1)
|
|
|
|
|
|
Consent of RSM US LLP, an independent registered public accounting firm
|
|
|
|
|
|
Power of Attorney (included as part of the signature page of this Registration Statement)
|
|
|
|
|
|
Yield10 Bioscience, Inc. 2018 Stock Option and Incentive Plan (filed as Exhibit 10.1 to the Registrant's Quarterly Report on 10-Q (File No. 001-33133) on August 9, 2018 and incorporated herein by reference)
|
|
YIELD10 BIOSCIENCE, INC.
|
|
|
|
|
|
By:
|
/s/ Oliver P. Peoples
|
|
|
Oliver P. Peoples
|
|
|
|
|
|
President and Chief Executive Officer
|
/s/ Oliver P. Peoples
|
|
President, Chief Executive Officer and Director
|
|
August 9, 2018
|
Oliver P. Peoples
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Charles B. Haaser
|
|
Vice President, Finance, and Chief Accounting Officer
|
|
August 9, 2018
|
Charles B. Haaser
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Joseph Shaulson
|
|
Director
|
|
August 9, 2018
|
Joseph Shaulson
|
|
|
|
|
|
|
|
|
|
/s/ Richard Hamilton
|
|
Director
|
|
August 9, 2018
|
Richard Hamilton
|
|
|
|
|
|
|
|
|
|
/s/ Peter N. Kellogg
|
|
Director
|
|
August 9, 2018
|
Peter N. Kellogg
|
|
|
|
|
|
|
|
|
|
/s/ Anthony J. Sinskey
|
|
Director
|
|
August 9, 2018
|
Anthony J. Sinskey
|
|
|
|
|
|
|
|
|
|
/s/ Robert L. Van Nostrand
|
|
Chairman
|
|
August 9, 2018
|
Robert L. Van Nostrand
|
|
|
|
|
1 Year Yield10 Bioscience Chart |
1 Month Yield10 Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions